论文部分内容阅读
目的比较骨桥蛋白(OPN)、黏蛋白1(MUC1)、细胞角蛋白19(CK-19)单独以及联合检测在乳腺癌早期诊断的临床应用价值。方法选择87例乳腺癌患者设为乳腺癌组,65例乳腺良性肿瘤患者为良性肿瘤组,72例健康体检妇女为对照组,反转录聚合酶链反应检测三组OPN、MUC1及CK-19表达情况,并比较三组研究对象OPN、MUC1及CK-19的阳性率,对OPN、MUC1及CK-19单独及联合检测对乳腺癌早期诊断进行方法学评价。结果乳腺癌组OPN、MUC1、CK-19阳性率均高于对照组及良性肿瘤组(P<0.05),对照组及良性肿瘤组OPN、MUC1、CK-19阳性率比较无统计学差异(P>0.05);三种肿瘤标志物任意组合的联合检测灵敏度均高于单独检测灵敏度,其中以三种肿瘤标志物联合检测灵敏度最高,达81.61%,相关约登指数为0.71,符合率为86.61%,阴性预测值为88.49%,均优于其他肿瘤标志物组合及单独检测。结论 OPN、MUC1及CK-19在乳腺癌的早期诊断有一定的临床应用价值,三种肿瘤标志物联合检测可大幅提高乳腺癌的检出率。
Objective To compare the clinical value of osteopontin (OPN), mucin 1 (MUC1), cytokeratin 19 (CK-19) alone and combined detection in the early diagnosis of breast cancer. Methods Eighty-seven breast cancer patients were selected as breast cancer group, 65 benign breast tumor patients as benign tumor group and 72 healthy women as control group. Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect OPN, MUC1 and CK-19 The positive rates of OPN, MUC1 and CK-19 in three groups were compared. The methodological evaluation of early diagnosis of breast cancer by OPN, MUC1 and CK-19 alone and in combination was evaluated. Results The positive rates of OPN, MUC1 and CK-19 in breast cancer group were significantly higher than those in control group and benign tumor group (P <0.05), while the positive rates of OPN, MUC1 and CK-19 in control group and benign tumor group were no significant difference (P > 0.05). The combined detection sensitivity of any combination of three tumor markers were higher than the sensitivity of single detection. The detection sensitivity of the three tumor markers was the highest, reaching 81.61%, the related Youden index was 0.71, the coincidence rate was 86.61% , The negative predictive value was 88.49%, which was better than other tumor marker combinations and single detection. Conclusion OPN, MUC1 and CK-19 have some clinical value in the early diagnosis of breast cancer. Combined detection of three tumor markers can significantly improve the detection rate of breast cancer.